Roquefort Therapeutics Divests Lyramid to Focus on Core Programs

Roquefort Investments PLC ( (GB:ROQ) ) just unveiled an announcement.

Roquefort Therapeutics has announced the sale of its subsidiary Lyramid Pty Ltd to Pleiades Pharma Limited for US$10.8 million, which will be paid in equity with potential upfront cash. This transaction allows Roquefort to focus on its other innovative programs while gaining a significant equity position in Pleiades, which holds the PapMV and S100A9 programs. This move is part of Roquefort’s strategy to develop and realize value through licensing and trade sales, enhancing its strategic positioning in the biotech industry.

More about Roquefort Investments PLC

Roquefort Therapeutics is a Main Market listed biotech company focused on developing first-in-class drugs within the high-value and high-growth immunology and oncology sectors. The company boasts a portfolio of five novel patent-protected pre-clinical anti-cancer medicines, including Midkine antibodies, RNA and mRNA therapeutics, STAT-6 siRNA therapeutics, and MK cell therapy.

YTD Price Performance: -6.17%

Average Trading Volume: 1,444,420

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £5.16M

Find detailed analytics on ROQ stock on TipRanks’ Stock Analysis page.